Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19

Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19
Zacks.com
1/28/2021
Shares of
Dr. Reddy’s Laboratories Ltd. RDY fell 4.13% after it announced the termination of the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting. The study is being conducted in partnership with Global Response Aid FZCO (GRA). However, shares of Dr. Reddy’s have soared 48.2% in the past yearcompared with the industry’s growth of 11.9%.
© Provided by Zacks.com
The data from the Kuwait CVD-04-CD-001 study involving moderate-severe COVID-19 hospitalized patients did not show a statistically significant difference for the primary endpoint (i.e. time to sustained hypoxia resolution) for Aviganversus Placebo. The subgroup analysis of the low-risk study cohort (n=181) showed a 3-day earlier discharge in the Avigan group compared to the placebo group. The subgroup analysis data during the initial interim analysis showed that an antiviral drug,Avigan, may be effective as part of early treatment initiation in COVID-19 patients and not effective in the late-stage hospital treatment for moderate and severe COVID-19 patients. The full data analysis on 353 subjects would be available by the end of February 2021.

Related Keywords

Kuwait ,Japan ,United States ,Japanese ,America , ,Reddys Laboratories Ltd ,Moderna Inc ,European Commission ,Reddys Laboratories Ltd Price ,Reddy Laboratories Ltd ,Fujifilm ,Global Response Aid ,North America ,Eli Lilly ,Zacks Rank ,Strong Buy ,குவைத் ,ஜப்பான் ,ஒன்றுபட்டது மாநிலங்களில் ,ஜப்பானிய ,அமெரிக்கா ,ரேட்திச் ஆய்வகங்கள் லிமிடெட் ,மாடர்னா இன்க் ,ஐரோப்பிய தரகு ,ரேட்திச் ஆய்வகங்கள் லிமிடெட் ப்ரைஸ் ,சிவப்பு ஆய்வகங்கள் லிமிடெட் ,புஜிஃபில்ம் ,உலகளாவிய பதில் உதவி ,வடக்கு அமெரிக்கா ,எலி லில்லி ,ஜாக்கக்ஸ் ரேங்க் ,வலுவான வாங்க ,